Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Has a diagnosis of hepatocellular carcinoma confirmed by radiology, histology, or cytology * Barcelona Clinic Liver Cancer (BCLC) Stage C disease without any distant or lymphatic metastasis , or BCLC Stage B disease not amenable to curative surgery * No previous systemic anticancer treatment or TACE treatment * Age ≥18 years * ECOG performance status: 0-1 * Child Pugh score≤7 * Has at least one measurable hepatocellular carcinoma (HCC) lesion based on RECIST 1.1 * Life expectancy ≥12 weeks. * Patients must be able to understand and willing to sign a written informed consent document Exclusion Criteria: * Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma * History of hepatic encephalopathy or liver transplantation * Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing drainage. * Untreated hepatitis infection: HBV DNA\>2000IU/mlor10000 copy/ml, HCV RNA\> 1000copy/ml, both HbsAg and anti-HCV body are positive. * Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * History of symptomatic interstitial lung disease or other conditions that may cause confusion when discovering or managing suspicious drug-related lung toxicity * With serious systemic diseases such as heart disease and cerebrovascular disease, and the condition is unstable or uncontrollable. * Evidence of active pulmonary tuberculosis (TB). * Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) * History of allergic reactions to related drugs * Pregnant women, nursing mothers